lysine
Lysing is an essential basic amino-acid encoded by codone AAA and AAG, and used in the biosynthesis of proteins. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken. In a clinical study lysine supplements was found to be an effective for reduction of occurrence, severity and healing time for recurrent HSV infection, however Cochrane Review concluded that the evidence is insufficient. Lysine was investigated for improving anxiety, ameliorating angina prectoris. Lysine acetylsalicylate has been used to treat pain and to detoxify the body after heroin use. Lysine clonixinate has been used for its analgesic properties for the treatment of migraine headaches and other painful conditions. However, limited clinical trials exist for these conditions. — NCATS
Clinical trial activity
22 trials · 21 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2005 (NCT02143908)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Radioprotective agent
Arginine/lysine reduce the lutetium (177Lu) oxodotreotide exposure in the kidneys by competing for glomerular filtration and protect the kidneys from radiation damage.
Chemistry & pharmacology
SMILES
NCCCC[C@H](N)C(O)=O- Mol. weight
- 146.1876 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLysine ↗
- NCATSK3Z4F929H6 ↗
- ChEMBLCHEMBL8085 ↗
- ChEMBLCHEMBL2105886 ↗
- ChEMBLCHEMBL2104640 ↗
Also known as
- 6-ammonio-l-norleucine
- 6-ammonio-l-norleucine
- l-2,6-diaminocaproic acid
- l-2,6-diaminocaproic acid
- l-lys
- l-lys
- l-lysin
- l-lysin
- l-lysine
- l-lysine
- l-lysine
- l-lysine
- l-lysine
- l-lysine
- l-lysine
- l-(+)-lysine
- lys
- lys
- lysina
- lysina
- lysine
- lysine
- lysine
- lysine
- lysine
- lysine
- lysine acetate
- lysine acetate
- lysine acetate
- lysine acid
- lysine acid
- lysine chloride
- lysine hcl
- lysine hydrochloride
- lysinum
- lysinum
- (s)-2,6-diaminohexanoic acid
- (s)-2,6-diaminohexanoic acid
- (s)-lysine
- (s)-lysine
- (s)-α,ε-diaminocaproic acid
- (s)-α,ε-diaminocaproic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06580145 | Phase 2 | Sep 30, 2024 | Emory University, National Institute of Mental Health (NIMH) |
| NCT06379217 | Phase 1 | Jul 29, 2024 | Novartis |
| NCT05210504 | Phase 1 | Mar 9, 2022 | Vanderbilt University |
| NCT04524442 | Phase 4 | Jan 27, 2021 | Advanced Accelerator Applications, Novartis |
| NCT04417218 | N/A | Jul 1, 2020 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Vanderbilt University |
| NCT04664712 | N/A | Sep 11, 2019 | ASL Bari, University of Bari |
| NCT03836495 | N/A | Feb 6, 2019 | American University of Beirut |
| NCT03826914 | N/A | Nov 6, 2018 | University of Manitoba |
| NCT03446651 | Early Phase 1 (Phase 1) | Jul 31, 2018 | Yale University |
| NCT03440970 | Early Phase 1 (Phase 1) | Jul 31, 2018 | Yale University |
| NCT03063476 | Phase 1 | Mar 1, 2017 | Vanderbilt University |
| NCT02756117 | Phase 1 | May 1, 2016 | Vanderbilt University |
| NCT02031354 | N/A | Jan 1, 2014 | Yale University |
| NCT02018575 | Phase 1 | Dec 1, 2013 | University of Toronto |
| NCT02008955 | N/A | Sep 1, 2012 | University of Toronto |
| NCT01579799 | N/A | Apr 1, 2012 | University of Zurich |
| NCT01776931 | N/A | Jan 1, 2012 | Canadian Institutes of Health Research (CIHR), University of British Columbia |
| NCT01474226 | Phase 1 | Jan 1, 2011 | University of Toronto |
| NCT01220388 | N/A | Oct 1, 2010 | Rouen Normandy University |
| NCT01155609 | N/A | Sep 1, 2010 | National Cancer Institute (NCI), University of Washington |